KN-93 (phosphate)
KN-93 phosphate is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM[1].
Product Specifications
CAS Number
[1913269-12-1]
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Autophagy; CaMK
Type
Reference compound
Related Pathways
Autophagy; Neuronal Signaling
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/KN-93-phosphate.html
Purity
99.72
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)
Smiles
OP(O)(O)=O.O=S(C1=CC=C(OC)C=C1)(N(C2=CC=CC=C2CN(C/C=C/C3=CC=C(Cl)C=C3)C)CCO)=O
Molecular Formula
C26H32ClN2O8PS
Molecular Weight
599.03
Precautions
H315, H319, H335
References & Citations
[1]Tombes RM, et al. G1 cell cycle arrest and apoptosis are induced in NIH 3T3 cells by KN-93, an inhibitor of CaMK-II (the multifunctional Ca2+/CaM kinase) . Cell Growth Differ. 1995 Sep;6 (9) :1063-70.|[2]Mamiya N, et al. Inhibition of acid secretion in gastric parietal cells by the Ca2+/calmodulin-dependent protein kinase II inhibitorKN-93. Biochem Biophys Res Commun. 1993 Sep 15;195 (2) :608-15.|[3]Anderson ME, et al. KN-93, an inhibitor of multifunctional Ca++/calmodulin-dependent protein kinase, decreases early afterdepolarizations in rabbit heart. J Pharmacol Exp Ther. 1998 Dec;287 (3) :996-1006.|[4]Li J, et al. Curcumin Attenuates Retinal Vascular Leakage by Inhibiting Calcium/Calmodulin-Dependent Protein Kinase II Activity in Streptozotocin-Induced Diabetes. Cell Physiol Biochem. 2016;39 (3) :1196-208.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CaMK II
Citation 01
Commun Biol. 2022 Jul 28;5 (1) :750.|Environ Res. 2024 Aug 15:255:119210.|Front Med. 2023 Apr;17 (2) :263-274.|Nat Commun. 2022 Jul 22;13 (1) :4255.|Nat Metab. 2020 Sep;2 (9) :918-933.|Sci Rep. 2023 Dec 7;13 (1) :21712.|Acta Pharmacol Sin. 2020 Feb;41 (2) :218-228.|Acta Pharmacol Sin. 2025 Jan;46 (1) :66-80.|Adv Funct Mater. 2024 Sep 02.|Adv Sci (Weinh) . 2024 Nov 8:e2405705.|Aging Cell. 2024 Nov 28:e14440.|Ann Transl Med. 2020 Mar;8 (5) :219.|Arch Toxicol. 2019 Jun;93 (6) :1697-1712. |Biochem Biophys Res Commun. 2022 Apr 20;615:136-142.|Biochem Biophys Res Commun. 2022 Jun 25;610:170-175.|Biochem Pharmacol. 2021 Oct:192:114722.|Biochem Pharmacol. 2025 Aug 8;242 (Pt 3) :117223.|Brain Res Bull. 2020 May;158:66-76.|Brain Res. 2024 Jan 1:1822:148665.|Cancer Med. 2024 Nov;13 (21) :e70286.|Cell Calcium. 2021 Dec:100:102483.|Cell Cycle. 2019 Nov;18 (21) :2986-2997.|Cell Death Dis. 2021 May 18;12 (6) :504.|Cell Death Discov. 2024 Mar 26;10 (1) :153.|Cell Mol Life Sci. 2022 Dec 1;79 (12) :613.|Cell Signal. 2023 Mar:103:110569.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Cell. 2022 Jun 23;185 (13) :2354-2369.e17.|Cell. 2024 Jun 20;187 (13) :3409-3426.e24.|Chin Med J (Engl) . 2024 Sep 3.|CNS Neurosci Ther. 2025 Nov;31 (11) :e70672.|Diabetes. 2018 Sep;67 (9) :1748-1760.|Diabetol Metab Syndr. 2023 Oct 28;15 (1) :217.|EMBO Mol Med. 2023 Jan 11;15 (1) :e16373.|Eur J Pharmacol. 2024 May 5:970:176483.|Eur J Pharmacol. 2025 Jan 9:177270.|Evid Based Complement Alternat Med. 2020 Dec 15:2020:8514926.|Exp Cell Res. 2018 Mar 15;364 (2) :198-207. |FASEB J. 2019 Dec;33 (12) :13644-13659.|FEBS Lett. 2022 Dec;596 (24) :3159-3175.|Free Radic Biol Med. 2025 Jul:234:248-263.|Front Genet. 2022 Aug 4;13:959360.|Front Pharmacol. 2018 Apr 12:9:362.|Front Pharmacol. 2022 Dec 15:13:996667.|Harvard Medical School LINCS LIBRARY|Int J Dent. 2025 Aug 15:2025:5566776.|J Agric Food Chem. 2019 Dec 26;67 (51) :14074-14085.|J Biochem Mol Toxicol. 2025 Oct;39 (10) :e70500.|J Cardiovasc Transl Res. 2024 Jun;17 (3) :540-553.|J Cell Biochem. 2019 Aug;120 (8) :13095-13106.|J Cell Mol Med. 2020 Aug;24 (16) :9287-9299.|J Control Release. 2025 Apr 11:113728.|J Endocrinol. 2018 Mar;236 (3) :151-165. |J Ethnopharmacol. 2024 Jan 10;318 (Pt B) :117016.|J Ethnopharmacol. 2025 Apr 9:345:119619.|J Mol Cell Cardiol. 2022 Mar:164:110-125.|J Mol Histol. 2021 Jun;52 (3) :555-566.|J Neurosci. 2022 Aug 3;42 (31) :6090-6107.|J Pineal Res. 2024 Aug;76 (5) :e12987.|Life Sci. 2020 Apr 1;246:117419.|Mol Cell Biol. 2024;44 (4) :149-163.|Nat Commun. 2025 Feb 7;16 (1) :1429.|Naunyn Schmiedebergs Arch Pharmacol. 2025 Nov 17.|Neuromodulation. 2025 Aug;28 (6) :962-975.|Neuropsychiatr Dis Treat. 2024 Sep 11:20:1693-1710.|Neurosci Bull. 2025 Jul 2.|Neurosci Lett. 2021 Apr 1:749:135699.|Neuroscience. 2022 May 10:490:89-99.|Neuroscience. 2025 Jul 23:579:129-143.|Oncol Rep. 2019 Jun;41 (6) :3413-3423.|Oxid Med Cell Longev. 2019 Dec 7;2019:2193019.|Oxid Med Cell Longev. 2021 Mar 29:2021:6678276.|Phytomedicine. 2024 Aug 22:134:155958.|Redox Biol. 2021 Oct:46:102115|Research Square Preprint. 2021 Oct.|Sci Adv. 2025 Jul 11;11 (28) :eadv5986.|Sci Total Environ. 2020 Feb 10;703:134702.|Signal Transduct Target Ther. 2025 Oct 28;10 (1) :357.|SSRN. 2024 Apr 4.|Toxicology. 2023 May 15:490:153514.|Transl Stroke Res. 2024 Apr;15 (2) :476-494.|University of Verona. 2025.|World J Diabetes. 2022 Apr 15;13 (4) :338-357.|Int Immunopharmacol. 2025 Aug 13:164:115330.|SSRN. 2025 Jul 2.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS2150855-01 0.1 mL
APC_Cy7-Linked Monoclonal Antibody to Integrin Alpha M (CD11b)
Ask
View Details 
MBS2150855-02 0.2 mL
APC_Cy7-Linked Monoclonal Antibody to Integrin Alpha M (CD11b)
Ask
View Details MBS2150855-03 0.5 mL
APC_Cy7-Linked Monoclonal Antibody to Integrin Alpha M (CD11b)
Ask
View Details